ALS
March 20 (Reuters) – Staff reviewers of U.S. drug regulator on Monday did not raise any new safety concerns about Biogen Inc’s (BIIB.O) experimental drug for treating a rare type of amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease.
Test tubes are seen in front of Amylyx logo in this illustration, July 24, 2022. REUTERS/Dado Ruvic/Illustration Register now for FREE unlimited access to Reuters.comRegister Sept 7 (Reuters) – Amylyx Pharmaceuticals Inc’s (AMLX.O . . .
Biogen logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration Register now for FREE unlimited access to Reuters.com Register July 26 (Reuters) – Biogen Inc’s (BIIB.O) treatment for . . .
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo Register now for FREE unlimited access to Reuters.com Register July 5 (Reuters) – Amylyx Pharmaceuticals
March 30 (Reuters) – A panel of outside advisers to the U.S. Food and Drug Administration on Wednesday voted against approving Amylyx Pharmaceuticals Inc’s (AMLX.O) drug for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. The FDA advisory committee voted 6 to 4 against the treatment, saying . . .
-
Pages